PURLs

Prescribing statins for patients with ACS? No need to wait

Author and Disclosure Information

 

References

WHAT'S NEW: Early statin administration 
is most effective

According to ACC/AHA guidelines, all patients with ACS should be receiving a statin by the time they are discharged. However, when to start the statin is not specified. This meta-analysis is the first report to show that administering a statin before PCI can significantly reduce the risk of subsequent MI.

CAVEATS: Benefits might vary
 with different statins


The studies evaluated in this meta-analysis used various statins and dosing regimens, which could have affected the results. However, sensitivity analyses found similar benefits across different types of statins. In addition, most of the included trials used high doses of statins, which minimized the potential discrepancy in outcomes from various dosing regimens. And while the included studies were not perfect, Navarese et al1 used reasonable methods to identify potential biases.

CHALLENGES TO IMPLEMENTATION: No barriers 
to starting statins earlier


Implementing this intervention may be as simple as editing a standard order. This meta-analysis also suggests that the earlier the intervention, the greater the benefit, which may be an argument for starting a statin when a patient first presents for evaluation for ACS, since the risks of taking a statin are quite low. We believe it would be beneficial if the next update of the ACC/AHA guidelines7 included this recommendation.

ACKNOWLEDGEMENT
The PURLs Surveillance System was supported in part by Grant Number UL1RR024999 from the National Center For Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Research Resources or the National Institutes of Health.

Pages

Copyright © 2014 Family Physicians Inquiries Network. All rights reserved.

Online-Only Materials

AttachmentSize
File JFP06312735_methodology43.11 KB

Recommended Reading

On-target glycemic control does not lessen excess mortality
MDedge Family Medicine
Evidence builds for risk-based antihypertension guidelines
MDedge Family Medicine
VIDEO: Study reignites dental antibiotic prophylaxis controversy
MDedge Family Medicine
CT screening not useful in high-risk diabetes patients
MDedge Family Medicine
VIDEO: Bioabsorbable polymer stents offer improved deliverability
MDedge Family Medicine
Children with NAFLD and high blood pressure more likely to develop cardiovascular issues
MDedge Family Medicine
Heart attack survival better with basic vs. advanced life support
MDedge Family Medicine
Oxygen may make STEMI worse
MDedge Family Medicine
What Matters: Salt substitutes to reduce blood pressure
MDedge Family Medicine
Pushing LDL below 25 mg/dL with alirocumab safe ‘so far’
MDedge Family Medicine

Related Articles

  • Applied Evidence

    Statin adverse effects: Sorting out the evidence

    Studies have assessed the incidence of everything from myopathy to diabetes and cataracts, but findings have been inconsistent. Here’s help in...

  • Applied Evidence

    Statin therapy: When to think twice

    While statins lower the risk of morbidity and mortality for millions of Americans, recent findings help clarify when a statin—or a statin and...